Fiore, Piera Filomena
Di Matteo, Sabina https://orcid.org/0000-0002-2586-7159
Tumino, Nicola
Mariotti, Francesca Romana
Pietra, Gabriella
Ottonello, Selene
Negrini, Simone
Bottazzi, Barbara
Moretta, Lorenzo
Mortier, Erwan
Azzarone, Bruno https://orcid.org/0000-0002-5962-3849
Clinical trials referenced in this document:
Documents that mention this clinical trial
Interleukin-15 and cancer: some solved and many unsolved questions
https://doi.org/10.1136/jitc-2020-001428
Documents that mention this clinical trial
Interleukin-15 and cancer: some solved and many unsolved questions
https://doi.org/10.1136/jitc-2020-001428
Documents that mention this clinical trial
Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors
https://doi.org/10.1136/jitc-2021-003388
First-in-human phase I/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15Rα, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumors
https://doi.org/10.1136/jitc-2023-007725
Emerging interleukin targets in the tumour microenvironment: implications for the treatment of gastrointestinal tumours
https://doi.org/10.1136/gutjnl-2023-329650
Phase 1 study evaluating the safety, preliminary efficacy, and pharmacodynamics of recombinant interleukin-15 in combination with nivolumab and ipilimumab in patients with refractory cancers
https://doi.org/10.1136/jitc-2025-013252
Interleukin-15 and cancer: some solved and many unsolved questions
https://doi.org/10.1136/jitc-2020-001428
Documents that mention this clinical trial
Short-course IL-15 given as a continuous infusion led to a massive expansion of effective NK cells: implications for combination therapy with antitumor antibodies
https://doi.org/10.1136/jitc-2020-002193
Interleukin-15 and cancer: some solved and many unsolved questions
https://doi.org/10.1136/jitc-2020-001428
Documents that mention this clinical trial
Interleukin-15 and cancer: some solved and many unsolved questions
https://doi.org/10.1136/jitc-2020-001428
Documents that mention this clinical trial
621 A phase I study of autologous activated NK cells ± rhIL15 in children and young adults with refractory solid tumors
https://doi.org/10.1136/jitc-2023-sitc2023.0621
Interleukin-15 and cancer: some solved and many unsolved questions
https://doi.org/10.1136/jitc-2020-001428
Documents that mention this clinical trial
Interleukin-15 and cancer: some solved and many unsolved questions
https://doi.org/10.1136/jitc-2020-001428
Documents that mention this clinical trial
Interleukin-15 and cancer: some solved and many unsolved questions
https://doi.org/10.1136/jitc-2020-001428
Documents that mention this clinical trial
34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part 1
https://doi.org/10.1186/s40425-019-0763-1
First-in-human phase I/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15Rα, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumors
https://doi.org/10.1136/jitc-2023-007725
Interleukin-15 and cancer: some solved and many unsolved questions
https://doi.org/10.1136/jitc-2020-001428